Featured Post from Georgia Tech College of Engineering

A new HIV treatment aimed at women could be on the horizon – let our experts explain for your stories.

Sep 12, 2019

2 min

Philip Santangelo



Did you know?


  • 18.8 million women and girls are living with HIV
  • AIDS-related illnesses are the leading cause of death among females between the age of 15 and 49
  • 1.8 million children are born with HIV, contracted from their mothers
  • In sub-Saharan Africa, 3 in 4 new HIV infections in teenagers are among girls
  • There are 5,000 new HIV infections per day


Women continue to be disproportionally affected by HIV around the world, but particularly in sub-Saharan Africa, where three in four new HIV infections are among young girls. For women seeking care in developing countries, preventing and managing HIV is an expensive proposition. Truvada, the pre-exposure HIV treatment drug commonly known as PrEP, costs about $1,500 a month and must be taken daily for continual HIV protection. Likewise, the antiretroviral therapies that attempt to control HIV infection are costly at nearly $20,000 a year. These oral medications as therapy are a non-starter in developing nations like Africa, where nearly 30 million people are infected with HIV.


But Phil Santangelo, biomedical engineering professor at Georgia Tech, has another approach in mind. He’s working on an aerosolized RNA-based HIV preventative that eventually could protect women against the disease. It’s applied vaginally and, currently, the aerosol has been tested in pre-clinical trials. The early results are promising; it’s been shown to create HIV antibodies that ward off the infection. It also has the potential to protect against genital herpes and other pathogens, depending on what protein the RNA encodes for.


“A single administration of this aerosol is showing expression of antibodies against HIV for up to three months in pre-clinical trials,” said Santangelo. “Our hope is that this will be more affordable, granting easier access to women in developing countries, especially. With women’s health at the forefront of many conversations today, this has the potential to revolutionize disease prevention.”


Eventually, Santangelo says RNA could be used for contraception as well – the RNA would express antibodies that inhibit sperm. Again, if birth control can’t be accessed in developing countries, a self-administered, inexpensive aerosol could change the lives of many women.


Are you a journalist covering this very important topic? If you have questions or would like to know more about the research being conducted at the Georgia Tech College of Engineering – then let our experts help.


Dr. Philip J. Santangelo is an Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering. Dr. Santangelo is an expert in the areas of therapeutics and vaccines and HIV/SIV and hRSV. He is available to speak with media regarding this emerging discovery - simply click on his icon to arrange an interview.



Connect with:
Philip Santangelo

Philip Santangelo

Professor, Biomedical Engineering

Philip J. Santangelo researches optical microscopy and in vivo imaging, RNA virus pathogenesis, HIV/SIV.

Therapeutics and VaccinesRNA RegulationRNA Virus PathogenesisOptical Microscopy and In Vivo ImagingHIV/SIV and hRSV

You might also like...

Check out some other posts from Georgia Tech College of Engineering

2 min

CRISPR is the genetic game changer – but are we ready?

CRISPR is here to stay – and the daily advances of this technology and stem cell therapy seem to be moving at a near exponential speed. “CRISPR Therapeutics of Zug, Switzerland, reported that one patient with sickle cell anemia and another with beta thalassemia appear to have benefited from the same CRISPR-based intervention for up to 9 months, STAT reports. (The company gave STAT an early look at the data but did not allow outside commenters to see the results.) Before the treatment, both patients required multiple infusions each year of red blood cells. CRISPR Therapeutics, collaborating with Vertex Pharmaceuticals, removed blood stem cells from their bodies and modified them with CRISPR to knock out a gene that shuts down production of fetal hemoglobin. When the edited cells were put back in each patient’s body through a stem cell transplant—which required a toxic chemotherapy to kill their own stem cells—both people produced high levels of fetal hemoglobin and no longer needed transfusions.” November 19 – Science Mag CRISPR and how it will shape the future of genetics, health care and society are the subject of great debate, hope and concern and if you are a journalist covering this topic and need an expert source for insight and perspective – let us help. Dr. Michael Davis researches cardiac regeneration, stem cell therapy and preservation at the Georgia Tech College of Engineering where he also is the Associate Chair for Graduate Studies in Biomedical Engineering. Michael is available to speak to media regarding this topic, simply click on his icon to arrange an interview.

2 min

It’s all eyes on Africa as the UN looks to find ways to ensure universal health care for all

It was a historic moment earlier this month as the United Nations and African Union pledged to pursue bolds goals that will strengthen global health and provide health care to all across Africa. “The Memorandum of Understanding we have signed today is an important step towards formalizing the cooperation between WHO and the African Union and to implementing the Addis Ababa Call to Action,” said the WHO chief. “The Addis Ababa Call to Action is a powerful commitment from African Union leaders to increase domestic financing for health, and to hold themselves accountable for that commitment”, he added. Following a political declaration on universal health coverage, which was approved in September by all UN Member States, the General Assembly adopted a global resolution to translate that commitment into reality by legislators in 140 countries. November 18 - UN News It’s indeed a bold declaration and one that will require prevention, infection control and affordable delivery of care. Key UN-AU collaboration specifics Provide technical expertise to the African Medicines Agency and create an environment to foster local production of medicines. Strengthen collaboration between WHO and the Africa Centers for Disease Control and Prevention – with a particular focus on emergency preparedness, to build defenses against epidemics and other health emergencies. Support the implementation of the Addis Ababa Call to Action on universal health coverage and the AU Declaration on Domestic Financing. The prospects are positive, but delivery will be a challenge, and if you are a journalist covering this topic and need an expert source for insight and perspective – let us help. Dr. Saad Bhamla is an Assistant Professor of Chemical & Biomolecular Engineering at the Georgia Tech College of Engineering where he also runs the Bhamla Lab that develops low cost tools for science education and global health.  Saad is available to speak to media regarding this topic, simply click on his icon to arrange an interview.

2 min

Locking down your data. Are lawmakers finally waking up to the importance of privacy?

Data collection and data control are becoming international issues. As the lucrative and important pieces of customer data collection become a priority for major tech and software companies – privacy and protection is now emerging as the key issue for international legislators. Just recently, Microsoft had to update several of its agreements with cloud customers and re-classify its role in Europe. Last month, as part of an enquiry that opened earlier this year, the European Data Protection Supervisor (EDPS) expressed 'serious concerns' over whether the relevant contractual terms were compliant with GDPR, and over Microsoft's role as a data processor or data controller for EU institutions. The report followed the publication of a series of papers by the Dutch Ministry of Justice and Security, suggesting that Office 365 was breaching GDPR by collecting 'functional and diagnostics data', including email subject lines and text run through a spell-checker. Microsoft has now acknowledged its position as a data controller - which has a higher bar for ensuring user data - when it comes to the provision of enterprise services. "In the [Online Services Terms] OST update, we will clarify that Microsoft assumes the role of data controller when we process data for specified administrative and operational purposes incident to providing the cloud services covered by this contractual framework, such as Azure, Office 365, Dynamics and Intune," says Julie Brill, Microsoft's corporate vice president for global privacy and regulatory affairs and chief privacy officer. "This subset of data processing serves administrative or operational purposes such as account management; financial reporting; combating cyber attacks on any Microsoft product or service; and complying with our legal obligations."  Forbes Magazine – November 18 Data collection and control are becoming big issues on a global scale as more and more governments are looking for consumer protection while companies are seeking the profit that comes from the information customers provide voluntarily and sometimes unwillingly . Are you a reporter covering technology, privacy and data collection and control?  Did you know that there is value in the results of spell-checkers and document review tools? If you have questions or need an expert source for insight and perspective – let us help. Dr. Rachel Cummings is an expert in data privacy, algorithmic economics, optimization, statistics, and information theory. Dr. Cummings is available to speak with media regarding data privacy and other topics, simply click on her icon to arrange an interview.

View all posts
Powered by